Industry News
ViaLase Initiates First U.S. IDE Trial Patient Treatment for Incision-Free Glaucoma Laser Procedure

ViaLase has announced the treatment of the first patient in its U.S. Investigational Device Exemptio...

read more
ViaLase Initiates First U.S. IDE Trial Patient Treatment for Incision-Free Glaucoma Laser Procedure
December 04, 2025
European Regulators Approve Pre-Filled Syringe Version of Byooviz, Lucentis Biosimilar

Samsung Bioepis has received a positive opinion from the European Medicines Agency’s Committee for M...

read more
European Regulators Approve Pre-Filled Syringe Version of Byooviz, Lucentis Biosimilar
December 03, 2025
Lotus Submits NDA for Presbyopia Treatment VIZZ in South Korea Under LENZ Partnership

Lotus Pharmaceutical and LENZ Therapeutics have announced the submission of a New Drug Application (...

read more
Lotus Submits NDA for Presbyopia Treatment VIZZ in South Korea Under LENZ Partnership
December 03, 2025
Kiora Pharmaceuticals Secures New U.S. Patent for Novel KIO-100 Formulations

Kiora Pharmaceuticals has received a new U.S. patent (Patent No. 12,472,263) covering additional and...

read more
Kiora Pharmaceuticals Secures New U.S. Patent for Novel KIO-100 Formulations
December 02, 2025
Belite Bio Reports Phase 3 Success for Tinlarebant in Stargardt Disease

Belite Bio has announced promising topline results from its global Phase 3 DRAGON trial, evaluating ...

read more
Belite Bio Reports Phase 3 Success for Tinlarebant in Stargardt Disease
December 02, 2025
Sandoz Launches Afqlir in Europe: A New Biosimilar Option for Retinal Disease Treatment

Sandoz has officially launched Afqlir, its biosimilar referencing aflibercept, across European marke...

read more
Sandoz Launches Afqlir in Europe: A New Biosimilar Option for Retinal Disease Treatment
November 28, 2025
Ripple Therapeutics Enters Evaluation and Licensing Agreement with Bausch + Lomb

Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug deliver...

read more
Ripple Therapeutics Enters Evaluation and Licensing Agreement with Bausch + Lomb
November 26, 2025
Inflammasome Therapeutics Completes Enrollment for Phase 2 Study of K8 in Geographic Atrophy

Inflammasome Therapeutics has announced the completion of patient enrollment in its multicenter Phas...

read more
Inflammasome Therapeutics Completes Enrollment for Phase 2 Study of K8 in Geographic Atrophy
November 26, 2025
Ocular Therapeutix Randomizes First Patient in HELIOS-3 Phase 3 Study for AXPAXLI in NPDR

Ocular Therapeutix has announced the randomization of the first patient in HELIOS-3, the second Phas...

read more
Ocular Therapeutix Randomizes First Patient in HELIOS-3 Phase 3 Study for AXPAXLI in NPDR
November 25, 2025
ArtIOLs®: Leading Surgeons Share Real-World Clinical Outcomes with Full Visual Range IOLs

A panel of leading ophthalmic surgeons shared their real-world experience with ArtIOLs® (Voptica S.L...

read more
ArtIOLs®: Leading Surgeons Share Real-World Clinical Outcomes with Full Visual Range IOLs
November 24, 2025
More